



## Expedeon AG announces conversion to registered shares

**Heidelberg, Germany and Cambridge, UK, 04 October 2019** – Expedeon AG (Frankfurt: EXNN; ISIN: DE000A2YN801; Prime Standard) today converted its bearer shares into registered shares. The registered shares of Expedeon AG are now under the new ISIN DE000A2YN801 (formerly: DE000A1RFM03) or WKN A2YN80 (formerly: A1RFM0). The stock symbol changes to EXNN (formerly: EXN). The conversion to registered shares is free of charge for shareholders.

The conversion from bearer shares to registered shares was approved at the Annual General Meeting on 9 July 2019. Registered shares require the maintenance of a share register in which the shareholders of Expedeon AG are entered, stating their name, date of birth and address as well as the number of shares they hold. Only shareholders who are entered on the share register are deemed to be shareholders of Expedeon AG and are entitled to attend and vote at Annual General Meetings. Entry on the share register is made by the shareholders' depositary banks. Further steps by the shareholders are not required.

The legal status of the shareholders entered on the share register will not be affected by the conversion to registered shares. Their shareholding in the company remains unchanged. Furthermore, the right of shareholders to sell their shares or to purchase shares is not restricted or impeded.

### For further information, please contact:

#### Expedeon AG

Dr. Heikki Lanckriet

CEO

Phone: +44 1223 873 364

Email: [heikki.lanckriet@expedeon.com](mailto:heikki.lanckriet@expedeon.com)

Investor website: [www.investors.expedeon.com](http://www.investors.expedeon.com)

#### MC Services AG (Investor Relations and International Media Relations)

Raimund Gabriel

Managing Partner

Phone: +49 89 210228 0

Email: [expedeon@mc-services.eu](mailto:expedeon@mc-services.eu)

#### About Expedeon AG: [www.expedeon.com](http://www.expedeon.com)

Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows

in genomics, proteomics and immunology, Expeleon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expeleon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expeleon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expeleon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expeleon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###